24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years

A Randomized, Double-blind, Double-dummy, 2-arm Parallel-group, Multicenter 24-week Study Comparing the Efficacy and Safety of AVE0010 to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 and Not Adequately Controlled With Metformin

The purpose of this study is to evaluate benefits and risks of lixisenatide (AVE0010), in comparison to sitagliptin, as an add-on treatment to metformin, in obese (body mass index [BMI] greater than or equal to 30 kilogram per square meter [kg/m^2]) type 2 diabetic patients less than 50 years of age, over a period of 24 weeks of treatment.

The primary objective of this study is to assess the efficacy of lixisenatide, in comparison to sitagliptin, as an add-on treatment to metformin on a composite endpoint of glycemic control in terms of glycosylated hemoglobin (HbA1c) and body weight, at Week 24.

Secondary objectives are to assess the effects of lixisenatide, in comparison to sitagliptin, as an add-on treatment to metformin on absolute changes in HbA1c values and body weight; fasting plasma glucose (FPG); plasma glucose, insulin, C-peptide, glucagon, and proinsulin during a 2-hour standardized meal test; insulin resistance assessed by homeostatic model assessment of insulin resistance (HOMA-IR); beta cell function assessed by homeostatic model assessment of beta-cell function (HOMA-beta); to evaluate safety, tolerability, and anti-lixisenatide antibody development.

Study Overview

• Status: Completed
• Conditions: Type 2 Diabetes Mellitus
• Intervention / Treatment: Device: Pen auto-injector; Drug: Lixisenatide (AVE0010); Drug: Sitagliptin Placebo; Drug: Metformin; Drug: Lixisenatide Placebo; Drug: Sitagliptin

• Study Type: Interventional
• Enrollment (Actual): 319
• Phase: Phase 3

Contacts and Locations

Study Locations

• Australia
  • Adelaide, Australia, 5000
    • Sanofi-Aventis Investigational Site Number 036006
  • Box Hill, Australia, 3128
    • Sanofi-Aventis Investigational Site Number 036001
  • Elizabeth Vale, Australia, 5112
    • Sanofi-Aventis Investigational Site Number 036004
  • Geelong, Australia, 3220
    • Sanofi-Aventis Investigational Site Number 036002
  • Meadowbrook, Australia, 4131
    • Sanofi-Aventis Investigational Site Number 036005
  • Sydney, Australia, 2006
    • Sanofi-Aventis Investigational Site Number 036003
• Brazil
  • Belem, Brazil, 66073-000
    • Sanofi-Aventis Investigational Site Number 076005
  • Brasilia, Brazil, 71625-009
    • Sanofi-Aventis Investigational Site Number 076001
  • Caxias Do Sul, Brazil, 95070-560
    • Sanofi-Aventis Investigational Site Number 076006
  • Curitiba, Brazil, 80060-900
    • Sanofi-Aventis Investigational Site Number 076003
  • Rio De Janeiro, Brazil, 20211-340
    • Sanofi-Aventis Investigational Site Number 076002
  • Sao Paulo, Brazil, 04024-002
    • Sanofi-Aventis Investigational Site Number 076004
  • Sao Paulo, Brazil, 05403-000
    • Sanofi-Aventis Investigational Site Number 076007
• Canada
  • Calgary, Canada, T2N 4N1
    • Sanofi-Aventis Investigational Site Number 124004
  • Hamilton, Canada, L8L 5G8
    • Sanofi-Aventis Investigational Site Number 124008
  • London, Canada, N6G 2M3
    • Sanofi-Aventis Investigational Site Number 124005
  • Montreal, Canada, H2W 1R7
    • Sanofi-Aventis Investigational Site Number 124006
  • Oakville, Canada, L6H 3P1
    • Sanofi-Aventis Investigational Site Number 124013
  • St-Romuald, Canada, G6W 5M6
    • Sanofi-Aventis Investigational Site Number 124002
  • Thornhill, Canada, L4J 8L7
    • Sanofi-Aventis Investigational Site Number 124012
  • Toronto, Canada
    • Sanofi-Aventis Investigational Site Number 124011
  • Vancouver, Canada, V5Z 1C6
    • Sanofi-Aventis Investigational Site Number 124003
  • Victoria, Canada, V8R 6V4
    • Sanofi-Aventis Investigational Site Number 124007
• Chile
  • Santiago, Chile, 7500347
    • Sanofi-Aventis Investigational Site Number 152001
  • Santiago, Chile, 7500710
    • Sanofi-Aventis Investigational Site Number 152004
  • Santiago, Chile, 8053095
    • Sanofi-Aventis Investigational Site Number 152003
  • Santiago, Chile
    • Sanofi-Aventis Investigational Site Number 152002
  • Santiago, Chile
    • Sanofi-Aventis Investigational Site Number 152005
• Germany
  • Berlin, Germany, 13125
    • Sanofi-Aventis Investigational Site Number 276002
  • Ludwigshafen, Germany, 67059
    • Sanofi-Aventis Investigational Site Number 276005
  • Schkeuditz, Germany, 04435
    • Sanofi-Aventis Investigational Site Number 276004
• Guatemala
  • Guatemala, Guatemala, 01010
    • Sanofi-Aventis Investigational Site Number 320002
  • Guatemala, Guatemala, 01014
    • Sanofi-Aventis Investigational Site Number 320001
  • Guatemala, Guatemala, 1010
    • Sanofi-Aventis Investigational Site Number 320004
  • Guatemala, Guatemala
    • Sanofi-Aventis Investigational Site Number 320005
  • Guatemala, Guatemala
    • Sanofi-Aventis Investigational Site Number 320006
• Mexico
  • Aguascalientes, Mexico, 20230
    • Sanofi-Aventis Investigational Site Number 484003
  • Chihuahua, Mexico, 31000
    • Sanofi-Aventis Investigational Site Number 484010
  • Chihuahua, Mexico, 31238
    • Sanofi-Aventis Investigational Site Number 484009
  • Df, Mexico, 03300
    • Sanofi-Aventis Investigational Site Number 484012
  • Merida, Mexico, 97000
    • Sanofi-Aventis Investigational Site Number 484008
  • México City, Mexico, 14050
    • Sanofi-Aventis Investigational Site Number 484011
  • Pachuca, Mexico, 42090
    • Sanofi-Aventis Investigational Site Number 484001
  • Pachuca, Mexico, 42090
    • Sanofi-Aventis Investigational Site Number 484005
  • Veracruz, Mexico, 91700
    • Sanofi-Aventis Investigational Site Number 484006
  • Zapopan, Mexico, 44030
    • Sanofi-Aventis Investigational Site Number 484002
• Peru
  • Lima, Peru
    • Sanofi-Aventis Investigational Site Number 604001
  • Lima, Peru, 27
    • Sanofi-Aventis Investigational Site Number 604005
  • Lima, Peru, Lima 27
    • Sanofi-Aventis Investigational Site Number 604003
  • Lima, Peru
    • Sanofi-Aventis Investigational Site Number 604002
  • Lima, Peru
    • Sanofi-Aventis Investigational Site Number 604004
• Poland
  • Bialystok, Poland, 15-435
    • Sanofi-Aventis Investigational Site Number 616002
  • Bydgoszcz, Poland, 85-822
    • Sanofi-Aventis Investigational Site Number 616001
  • Warszawa, Poland, 02-507
    • Sanofi-Aventis Investigational Site Number 616006
  • Wroclaw, Poland, 50-127
    • Sanofi-Aventis Investigational Site Number 616003
• Romania
  • Bacau, Romania, 600164
    • Sanofi-Aventis Investigational Site Number 642004
  • Bucuresti, Romania, 020475
    • Sanofi-Aventis Investigational Site Number 642006
  • Bucuresti, Romania, 022441
    • Sanofi-Aventis Investigational Site Number 642008
  • Iasi, Romania, 700515
    • Sanofi-Aventis Investigational Site Number 642010
  • Ploiesti, Romania, 100097
    • Sanofi-Aventis Investigational Site Number 642009
  • Resita, Romania, 320076
    • Sanofi-Aventis Investigational Site Number 642001
  • Suceava, Romania, 720262
    • Sanofi-Aventis Investigational Site Number 642005
  • Timisoara, Romania, 300593
    • Sanofi-Aventis Investigational Site Number 642007
• Russian Federation
  • Kazan, Russian Federation, 420012
    • Sanofi-Aventis Investigational Site Number 643002
  • St-Petersburg, Russian Federation, 195257
    • Sanofi-Aventis Investigational Site Number 643003
  • St-Petersburg, Russian Federation, 198013
    • Sanofi-Aventis Investigational Site Number 643005
  • St. Petersburg, Russian Federation, 194358
    • Sanofi-Aventis Investigational Site Number 643001
  • Tyumen, Russian Federation, 625023
    • Sanofi-Aventis Investigational Site Number 643004
• Ukraine
  • Chernivtsi, Ukraine, 58022
    • Sanofi-Aventis Investigational Site Number 804003
  • Kiev, Ukraine, 2091
    • Sanofi-Aventis Investigational Site Number 804001
  • Kyiv, Ukraine, 31156
    • Sanofi-Aventis Investigational Site Number 804004
• United States
  • Alabama
    • Montgomery, Alabama, United States, 36109
      • Sanofi-Aventis Investigational Site Number 840019
    • Muscle Shoals, Alabama, United States, 35661
      • Sanofi-Aventis Investigational Site Number 840003
  • Arizona
    • Mesa, Arizona, United States, 85206
      • Sanofi-Aventis Investigational Site Number 840022
  • California
    • Anaheim, California, United States, 92801
      • Sanofi-Aventis Investigational Site Number 840011
    • Paramount, California, United States, 90723
      • Sanofi-Aventis Investigational Site Number 840014
    • Redlands, California, United States, 92374
      • Sanofi-Aventis Investigational Site Number 840027
  • Georgia
    • Augusta, Georgia, United States, 30909
      • Sanofi-Aventis Investigational Site Number 840021
    • Roswell, Georgia, United States, 30076
      • Sanofi-Aventis Investigational Site Number 840007
  • Illinois
    • Chicago, Illinois, United States, 60610
      • Sanofi-Aventis Investigational Site Number 840016
    • Chicago, Illinois, United States, 60616
      • Sanofi-Aventis Investigational Site Number 840018
  • Indiana
    • Evansville, Indiana, United States, 47714
      • Sanofi-Aventis Investigational Site Number 840001
  • Louisiana
    • Baton Rouge, Louisiana, United States, 70808
      • Sanofi-Aventis Investigational Site Number 840002
  • Michigan
    • Clarkston, Michigan, United States, 48346
      • Sanofi-Aventis Investigational Site Number 840031
  • Missouri
    • Florissant, Missouri, United States, 63031
      • Sanofi-Aventis Investigational Site Number 840020
  • Montana
    • Butte, Montana, United States, 59701
      • Sanofi-Aventis Investigational Site Number 840006
  • Ohio
    • Perrysburg, Ohio, United States, 43551
      • Sanofi-Aventis Investigational Site Number 840026
  • Oregon
    • Medford, Oregon, United States, 97504
      • Sanofi-Aventis Investigational Site Number 840004
  • Pennsylvania
    • Altoona, Pennsylvania, United States, 16602
      • Sanofi-Aventis Investigational Site Number 840025
  • Tennessee
    • Brentwood, Tennessee, United States, 37207
      • Sanofi-Aventis Investigational Site Number 840009
  • Texas
    • Dallas, Texas, United States, 75230
      • Sanofi-Aventis Investigational Site Number 840008
    • San Antonio, Texas, United States, 78229
      • Sanofi-Aventis Investigational Site Number 840010

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 49 years (Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion criteria

• Type 2 diabetes mellitus, diagnosed for at least 1 year at the time of screening visit, insufficiently controlled with metformin at a stable dose of at least 1.5 gram/day (g/day) for at least 3 months prior to the screening visit
• Patients with obesity (BMI greater than equal to [>=] 30 kg/m^2) and aged from 18 years to less than 50 years

Exclusion criteria

• HbA1c less than (<) 7.0 percent (%) or HbA1c greater than (>) 10% at screening
• Type 1 diabetes mellitus
• Pregnant or breastfeeding women or women of childbearing potential with no effective contraceptive method
• FPG at screening >250 milligram/deciliter (mg/dL) (>13.9 millimole/ liter [mmol/L])
• Weight change of more than 5 kg during the 3 months preceding the screening visit
• History of unexplained pancreatitis, chronic pancreatitis, pancreatectomy, stomach/gastric surgery, inflammatory bowel disease, personal or family history of medullary thyroid cancer (MTC) or genetic conditions that predispose to MTC (for example, multiple endocrine neoplasia syndromes)
• History of metabolic acidosis, including diabetic ketoacidosis within 1 year prior to screening
• Hemoglobinopathy or hemolytic anemia or receipt of blood or plasma products within 3 months prior to the time of screening
• Within the last 6 months prior to screening: history of myocardial infarction, stroke, or heart failure requiring hospitalization
• Known history of drug or alcohol abuse within 6 months prior to the time of screening
• Any clinically significant abnormality identified on physical examination, laboratory tests, electrocardiogram (ECG) or vital signs at the time of screening that in the judgment of the investigator or any sub-investigator could have precludes safe completion of the study or constrains efficacy assessment such as major systemic diseases, presence of clinically significant diabetic retinopathy or presence of macular edema likely to require laser treatment within the study period
• Uncontrolled or inadequately controlled hypertension at the time of screening with a resting systolic or diastolic blood pressure >180 millimeter of mercury (mmHg) or >110 mmHg, respectively
• Laboratory findings at the time of screening : Amylase and/or lipase >3 times the upper limit of normal (ULN) laboratory range; alanine aminotransferase (ALT): >3 times ULN; total bilirubin: >1.5 times ULN (except in case of Gilbert's syndrome); hemoglobin <11 gram/deciliter and/or neutrophils <1500 per cubic millimeter (mm^3) and/or platelets <100 000/mm^3; positive test for Hepatitis B surface antigen (HBsAg) and/or Hepatitis C antibody (HCAb), positive serum pregnancy test in females of childbearing potential, and calcitonin >=20 picogram per milliliter (pg/mL) (5.9 picomole per liter)
• Patients who are considered by the investigator or any sub-investigator as inappropriate for the study for any reason (for example, impossibility to meet specific protocol requirements [such as scheduled visits, being able to do self-injections], likelihood of requiring treatment during the screening phase and treatment phase with drugs not permitted by the clinical study protocol, investigator or any sub-investigator, pharmacist, study coordinator, other study staff or relative thereof directly involved in the conduct of the protocol)
• Use of other oral or injectable antidiabetic or hypoglycemic agents than metformin (for example, sulfonylurea, alpha glucosidase inhibitor, thiazolidinedione, exenatide, dipeptidyl peptidase IV (DPP-IV) inhibitors, insulin) within 3 months prior to the time of screening
• History of bariatric surgery, anti-obesity treatment, or unstable diet within 3 months prior to the time of screening
• Use of systemic glucocorticoids (excluding topical application or inhaled forms) for one week or more within 3 months prior to the time of screening
• Use of any investigational drug within 3 months prior to screening
• Clinically relevant history of gastrointestinal disease associated with prolonged nausea and vomiting, including (but not limited to): gastroparesis, unstable (that is, worsening) and not controlled (that is, prolonged nausea and vomiting) gastroesophageal reflux disease requiring medical treatment, within 6 months prior to the time of screening
• Any previous treatment with lixisenatide (for example, participation in a previous study with lixisenatide)
• Allergic reaction to any glucagon like peptide-1 (GLP 1) agonist in the past (for example, exenatide, liraglutide) or to metacresol
• History of a serious hypersensitivity reaction to sitagliptin
• Moderate or severe renal impairment (creatinine clearance inferior to 50 milliliter/minute [mL/min])
• Additional exclusion criteria at the end of the run-in phase: informed consent withdrawal; lack of compliance during the single-blind placebo run-in period (>2 injections missed or >2 capsules missed); and patient with any adverse event which could have precludes the inclusion in the study, as assessed by the investigator

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Lixisenatide; 2-step initiation regimen of lixisenatide along with sitagliptin placebo: lixisenatide 10 microgram (mcg) once daily (QD) for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to Week 24 along with placebo matching to sitagliptin 100 milligram (mg) capsule orally QD up to Week 24.	Device: Pen auto-injector; Other Names: OptiClik®; Drug: Lixisenatide (AVE0010); Self-administered by subcutaneous injections once daily within the hour preceding breakfast.; Drug: Sitagliptin Placebo; Administered orally once a day in the morning with or without food at approximately the same time each day.; Drug: Metformin; Metformin to be continued at stable dose (at least 1.5 gram per day) up to Week 24.
Active Comparator: Sitagliptin; Sitagliptin along with 2-step initiation regimen of volume matching lixisenatide placebo: sitagliptin 100 mg capsule orally QD up to Week 24 along with volume matching lixisenatide placebo 10 mcg QD for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to Week 24.	Device: Pen auto-injector; Other Names: OptiClik®; Drug: Metformin; Metformin to be continued at stable dose (at least 1.5 gram per day) up to Week 24.; Drug: Lixisenatide Placebo; Self-administered by subcutaneous injections once daily within the hour preceding breakfast.; Drug: Sitagliptin; Administered orally once a day in the morning with or without food at approximately the same time each day.; Other Names: Januvia®

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of Patients With Glycosylated Hemoglobin (HbA1c) Level Less Than 7% and at Least 5% Weight Loss From Baseline at Week 24	Percentage of patients who met both criteria (HbA1c <7% at Week 24 and at least 5% weight loss from baseline at Week 24) is reported. The on-treatment period for this efficacy variable is the time from the first dose of study drug up to 3 days after the last dose of study drug or up to the introduction of rescue therapy, whichever is the earliest.	Week 24

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Absolute Change From Baseline in HbA1c at Week 24	Absolute change = HbA1c value at Week 24 minus HbA1c value at baseline. The on-treatment period for this efficacy variable is the time from the first dose of study drug up to 3 days after the last dose of study drug or up to the introduction of rescue therapy, whichever is the earliest.	Baseline, Week 24
Change From Baseline in Body Weight at Week 24	Change was calculated by subtracting baseline value from Week 24 value. The on-treatment period for this efficacy variable is the time from the first dose of study drug up to 3 days after the last dose of study drug or up to the introduction of rescue therapy, whichever is the earliest.	Baseline, Week 24
Change From Baseline in 2-hour Postprandial Plasma Glucose (PPG) at Week 24	The 2-hour PPG test measured blood glucose 2 hours after eating a standardized meal. Change was calculated by subtracting baseline value from Week 24 value. The on-treatment period for this efficacy variable is the time from the first dose of study drug up to the last dosing day of the study drug or up to the introduction of rescue therapy, whichever is the earliest.	Baseline, Week 24
Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24	Change was calculated by subtracting baseline value from Week 24 value. The on-treatment period for this efficacy variable is the time from the first dose of study drug up to 1 day after the last dose of study drug or up to the introduction of rescue therapy, whichever is the earliest.	Baseline, Week 24
Change From Baseline in Glucose Excursion at Week 24	Glucose excursion = 2-hour PPG minus plasma glucose 30 minutes prior to the standardized meal test, before study drug administration. Change was calculated by subtracting baseline value from Week 24 value. The on-treatment period for this efficacy variable is the time from the first dose of study drug up to the last dosing day of the study drug or up to the introduction of rescue therapy, whichever is the earliest.	Baseline, Week 24
Change From Baseline in Fasting Plasma Insulin (FPI) and 2-hour Postprandial Plasma Insulin (PPI) at Week 24	Change was calculated for fasting plasma insulin and 2-hour post prandial plasma insulin by subtracting the baseline value from Week 24 value. The on-treatment period for this efficacy variable is the time from the first dose of study drug up to the last dosing day of the study drug or up to the introduction of rescue therapy, whichever is the earliest.	Baseline, Week 24
Change From Baseline in Fasting C-peptide and 2-hour Postprandial C-peptide at Week 24	Change was calculated for fasting C-peptide and 2-hour postprandial C-peptide by subtracting the baseline value from Week 24 value. The on-treatment period for this efficacy variable is the time from the first dose of study drug up to the last dosing day of study drug or up to the introduction of rescue therapy, whichever is the earliest.	Baseline, Week 24
Change From Baseline in Fasting Glucagon and 2-hour Postprandial Glucagon at Week 24	Change was calculated for fasting glucagon and 2-hour postprandial glucagon by subtracting the baseline value from Week 24 value. The on-treatment period for this efficacy variable is the time from the first dose of study drug up to the last dosing day of study drug or up to the introduction of rescue therapy, whichever is the earliest.	Baseline, Week 24
Change From Baseline in Fasting Proinsulin and 2-hour Postprandial Proinsulin at Week 24	Change was calculated for fasting proinsulin and 2-hour postprandial proinsulin by subtracting the baseline value from Week 24 value. The on-treatment period for this efficacy variable is the time from the first dose of the study drug up to the last dosing day of study drug or up to the introduction of rescue therapy, whichever is the earliest.	Baseline, Week 24
Change From Baseline in Insulin Resistance Assessed by Homeostasis Model Assessment- Insulin Resistance (HOMA-IR) at Week 24	HOMA-IR was derived from FPG and FPI as: (FPI [micro units per milliliter]*FPG [mmol/L]) divided by 22.5. Change was calculated for HOMA-IR by subtracting the baseline value from Week 24 value. The on-treatment period for this efficacy variable is the time from the first dose of study drug up to the last dosing day of study drug or up to the introduction of rescue therapy, whichever is the earliest.	Baseline, Week 24
Change From Baseline in Beta Cell Function Assessed by Homeostasis Model Assessment-Beta (HOMA-beta) at Week 24	HOMA-beta was derived from FPG and FPI as: (20*FPI [micro units/milliliter]) divided by (FPG [mmol/L] minus 3.5). Change was calculated for HOMA-beta by subtracting the baseline value from Week 24 value. The on-treatment period for this efficacy variable is the time from the first dose of study drug up to the last dosing day of study drug or up to the introduction of rescue therapy, whichever is the earliest.	Baseline, Week 24
Percentage of Patients With Glycosylated Hemoglobin (HbA1c) Level Less Than or Equal to 6.5% at Week 24	The on-treatment period for this efficacy variable is the time from the first dose of study drug up to 3 days after the last dose of study drug or up to the introduction of rescue therapy, whichever is the earliest.	Week 24
Percentage of Patients Requiring Rescue Therapy During 24-Week Period	Routine fasting self-measured plasma glucose (SMPG) and central laboratory FPG (and HbA1c after week 12) values were used to determine the requirement of rescue medication. If fasting SMPG value exceeded the specified limit for 3 consecutive days, the central laboratory FPG (and HbA1c after week 12) were performed. Threshold values - from baseline to Week 8: fasting SMPG/FPG >270 milligram/deciliter (mg/dL) (15.0 mmol/L), from Week 8 to Week 12: fasting SMPG/FPG >240 mg/dL (13.3 mmol/L), and from Week 12 to Week 24: fasting SMPG/FPG >200 mg/dL (11.1 mmol/L) or HbA1c >8.5%.	Baseline up to Week 24

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Patients With Symptomatic Hypoglycemia and Severe Symptomatic Hypoglycemia	Symptomatic hypoglycemia was an event with clinical symptoms that were considered to result from a hypoglycemic episode with an accompanying plasma glucose less than 60 mg/dL (3.3 mmol/L) or associated with prompt recovery after oral carbohydrate, intravenous glucose, or glucagon administration if no plasma glucose measurement was available. Severe symptomatic hypoglycemia was symptomatic hypoglycemia event in which the patient required the assistance of another person and was associated with either a plasma glucose level below 36 mg/dL (2.0 mmol/L) or prompt recovery after oral carbohydrate, intravenous glucose, or glucagon administration, if no plasma glucose measurement was available.	First dose of study drug up to 3 days after the last dose administration
Percentage of Patients With Glycosylated Hemoglobin (HbA1c) Level Less Than 7% at Week 24	The on-treatment period for this efficacy variable is the time from the first dose of study drug up to 3 days after the last dose of study drug or up to the introduction of rescue therapy, whichever is the earliest.	Week 24
Percentage of Patients With at Least 5% Weight Loss From Baseline at Week 24	The on-treatment period for this efficacy variable is the time from the first dose of study drug up to 3 days after the last dose of study drug or up to the introduction of rescue therapy, whichever is the earliest.	Baseline, Week 24
Change From Baseline in Fasting Proinsulin-to-insulin Ratio and 2-hour Postprandial Proinsulin-to-insulin Ratio at Week 24	Change was calculated by subtracting baseline value from Week 24 value. The on-treatment period for this efficacy variable is the time from the first dose of study drug up to the last dosing day of the study drug or up to the introduction of rescue therapy, whichever is the earliest.	Baseline, Week 24

Collaborators and Investigators

• Sponsor: Sanofi

Study record dates

Study Major Dates

• Study Start: August 1, 2009
• Primary Completion (Actual): March 1, 2011
• Study Completion (Actual): March 1, 2011

Study Registration Dates

• First Submitted: September 14, 2009
• First Submitted That Met QC Criteria: September 14, 2009
• First Posted (Estimate): September 15, 2009

Study Record Updates

• Last Update Posted (Estimate): October 11, 2016
• Last Update Submitted That Met QC Criteria: August 18, 2016
• Last Verified: August 1, 2016

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Glucose Metabolism Disorders; Metabolic Diseases; Endocrine System Diseases; Diabetes Mellitus; Diabetes Mellitus, Type 2; Hypoglycemic Agents; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Protease Inhibitors; Incretins; Dipeptidyl-Peptidase IV Inhibitors; Metformin; Sitagliptin Phosphate; Lixisenatide
• Other Study ID Numbers: EFC10780; EudraCT:2008-007 334-22